Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade

Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade

Background Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesional agent for the treatment of various (sub)cutaneous malignancies. Previous work has shown that intratumoral (I.T.) injection of TT causes vascular disruption with concomitant...

Full description

Saved in:
Bibliographic Details
Main Authors: Kevin Hendrawan, Kelly M Brooks, Pei-Yi Yap, Blake Ferguson, Motoko Koyama, Herlina Handoko, Jenny Johns, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Yi Chieh Lim, Giovanni Appendino, Jason K Cullen, Zara C Bruce, Steven M Ogbourne, Paul W Reddell, Glen M Boyle, Peter G Parsons, Jacinta L Simmons, Emily S Wilson, Marjorie M A de Souza, Tam Hong Nguyen, Alberto Pagani, Victoria A Gordon
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e006602.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/4/e006602.full

Similar Items